Oric
formerly ORIC PharmaceuticalsIPOHOME - ORIC Pharmaceuticals
Public · South San Francisco, United States · Founded 2014 · $647.0M raised
- Headquarters
- South San Francisco, California
- Employees
- 51–200
- Founded
- 2014
- Business Model
- B2B
- Website
- oricpharma.com
- Total Funding
- $647.0M
- Last Round
- $264.0M Private EquityFeb 2026
- Rounds
- 7
- Type
- Public
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. The company's resistance platform targets three mechanisms: innate resistance (unaddressed oncogenic drivers), acquired resistance (induced or enriched oncogenic drivers arising in response to treatment), and bypass resistance (compensatory signaling pathways activated in response to treatment). ORIC's lead programs include rinzimetostat (ORIC-944), a PRC2 inhibitor in Phase 1b combination studies in metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant EGFR/HER2 inhibitor in Phase 1b studies across multiple NSCLC patient populations including EGFR exon 20 and PACC mutations. The company is headquartered in South San Francisco, California and is publicly traded on Nasdaq.
Summary
Oric is a Biotech company based in South San Francisco, United States, founded in 2014. It has raised $647.0M in total across 7 rounds, most recently a $264.0M Private Equity round in Feb 2026. Investors include The Column Group, ArrowMark Partners and EcoR1 Capital.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding & Exit History
Feb 2026
Sign up to see all 9 events
Funding: Series A through Private Equity. Amounts, valuations, and investors where available.
Investors
The Column Group
3 rounds
ArrowMark Partners
1 round
EcoR1 Capital
4 rounds
Frazier Life Sciences
2 rounds
Viking Global
2 rounds
Venrock
1 round
Boxer Capital
1 round
Nextech Invest
1 round
Commodore Capital
1 round
Fidelity Management
1 round
New Enterprise Associates
1 round
Correlation Ventures
1 round
Topspin Partners
1 round
OrbiMed
1 round
Similar Companies
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/oric"><img src="https://indexed.vc/api/badge/company/oric" alt="Oric on Indexed.vc" width="260" height="76" /></a>